Evidence map›Paper›PMID 40525441›Full record

ReviewCurrent medicinal chemistry2025

Analysis of Pan-Specific Inhibitors of Oncogenic Mutant Forms of KRAS GTPase.

Ilya A Eliseev, Dmitrii O Shkil, Valentina S Shumakova, Vladimir V Chernyshov, Konstantin V Balakin, Roman A Ivanov

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ilya A EliseevMedicinal Biotechnology Department, Sirius University of Science and Technology, Olimpiyskiy ave. 1, Sirius, Krasnodar Region, 354340, Russia.ORCID 0009-0002-4664-818X
Dmitrii O ShkilDepartment of Innovative Pharmaceuticals, Medical Technology and Biotechnology, Moscow Institute of Physics and Technology, Institutsky Lane 9, Dolgoprudny, Moscow Region, 141700, Russia.
Valentina S ShumakovaMedicinal Biotechnology Department, Sirius University of Science and Technology, Olimpiyskiy ave. 1, Sirius, Krasnodar Region, 354340, Russia.ORCID 0009-0003-1825-7517
Vladimir V ChernyshovMedicinal Biotechnology Department, Sirius University of Science and Technology, Olimpiyskiy ave. 1, Sirius, Krasnodar Region, 354340, Russia.
Konstantin V BalakinDepartment of Innovative Pharmaceuticals, Medical Technology and Biotechnology, Moscow Institute of Physics and Technology, Institutsky Lane 9, Dolgoprudny, Moscow Region, 141700, Russia.ORCID 0000-0001-7611-0802
Roman A IvanovMedicinal Biotechnology Department, Sirius University of Science and Technology, Olimpiyskiy ave. 1, Sirius, Krasnodar Region, 354340, Russia.ORCID 0000-0002-9573-4183

Funding

Ministry of Science and Higher Education of the Russian Federation 075-10-2025-017
6 · The paper itself

Abstract

The KRAS protein is one of the key targets in cancer therapy. The clinical application of covalent KRAS inhibitors (sotorasib, adagrasib) is limited to the treatment of only certain KRAS

Indexed as

Antineoplastic AgentsEnzyme InhibitorsNeoplasmsProto-Oncogene Proteins p21(ras)AnimalsHumansMutationStructure-Activity RelationshipAntineoplastic AgentsEnzyme InhibitorsKRAS protein, humanProto-Oncogene Proteins p21(ras)BI-2865.Cancerdrug developmentKRASKRAS-G12X/G13D/Q61Hmutationspan-KRAS inhibitorspatentsRASSAR analysis

Identifiers

PMID40525441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.